Background Immunotherapy has determined unprecedented long-term responses in several
hematological and solid tumors. In the MOUSEION-03 study, we conducted a meta-analysis …

Even though the immuno-oncology (IO) era has achieved many successes, some signs of
research development deceleration are arising. Recently, the number of FDA …

The gut microbiome has been shown to influence the response of tumors to anti–PD-1
(programmed cell death–1) immunotherapy in preclinical mouse models and observational …

The last 5 years have witnessed relevant advances in the systemic treatment of
hepatocellular carcinoma. New data have emerged since the development of the EASL …

Objective Programmed death 1 and its ligand 1 (PD-1/PD-L1) immunotherapy is promising
for late-stage lung cancer treatment, however, the response rate needs to be improved. Gut …

Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and the third
leading cause of cancer-related death worldwide. Single-agent anti-PD-1 immune …

Immune checkpoint inhibitors (ICIs), by reinvigorating CD8+ T cell mediated immunity, have
revolutionized cancer therapy. Yet, the systemic CD8+ T cell distribution, a potential …

Circulating tumor DNA (ctDNA) has emerged as a biomarker with wide-ranging applications
in cancer management. While its role in guiding precision medicine in certain tumors via …

The primary endpoint of MOUSEION-01 was to assess overall survival (OS) in male and
female patients receiving immune checkpoint inhibitors versus control treatments …

Defects in pathways governing genomic fidelity have been linked to improved response to
immune checkpoint blockade therapy (ICB). Pathogenic POLE/POLD1 mutations can cause …